Brokerages Set Kenvue Inc. (NYSE:KVUE) PT at $20.23

by · The Markets Daily

Kenvue Inc. (NYSE:KVUE – Get Free Report) has been given an average rating of “Hold” by the eighteen ratings firms that are covering the company, MarketBeat.com reports. Twelve investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $20.2333.

A number of equities analysts have recently weighed in on KVUE shares. The Goldman Sachs Group lowered their target price on Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, October 2nd. Jefferies Financial Group reduced their price objective on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a report on Monday, October 27th. Barclays upped their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Bank of America cut their price target on Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research note on Wednesday, October 8th. Finally, Citigroup lowered their price objective on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th.

Get Our Latest Stock Analysis on KVUE

Kenvue Price Performance

Kenvue stock opened at $17.32 on Wednesday. The stock has a market capitalization of $33.18 billion, a price-to-earnings ratio of 23.09 and a beta of 0.59. Kenvue has a 52-week low of $14.02 and a 52-week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The stock’s 50 day moving average price is $16.20 and its two-hundred day moving average price is $19.06.

Kenvue (NYSE:KVUE – Get Free Report) last released its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. Kenvue’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities analysts predict that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th were given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. The ex-dividend date of this dividend was Wednesday, November 12th. Kenvue’s dividend payout ratio is presently 110.67%.

Institutional Trading of Kenvue

Several institutional investors have recently made changes to their positions in the company. Atria Wealth Solutions Inc. lifted its position in shares of Kenvue by 48.0% during the first quarter. Atria Wealth Solutions Inc. now owns 27,022 shares of the company’s stock valued at $648,000 after purchasing an additional 8,765 shares in the last quarter. AlphaCore Capital LLC purchased a new stake in Kenvue in the 1st quarter valued at about $115,000. Townsquare Capital LLC lifted its position in shares of Kenvue by 8.6% during the 1st quarter. Townsquare Capital LLC now owns 31,273 shares of the company’s stock worth $750,000 after buying an additional 2,477 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Kenvue by 39.2% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,030 shares of the company’s stock worth $696,000 after buying an additional 8,178 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Kenvue by 11.6% in the first quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company’s stock valued at $597,395,000 after acquiring an additional 2,597,920 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

(Get Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Further Reading